The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford Covid-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated 77 percent efficacy in children over 12 months of follow-up.
A USA Today report found that from January through May 2020, 28 generic drugs in 405 dosages made the U.S. Food and Drug Administration’s list of drugs in shortage.
A lot of attention shifted to the malaria drug hydroxychloroquine for treatment of COVID-19, the disease caused by the novel coronavirus.
Researchers with the Pasteur Institute and CNRS (French National Center for Scientific Research) in France recently identified molecules that can inhibit DNA methylation and kill even the most resistant of the malaria parasites, Plasmodium falciparum.
The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.
GlaxoSmithKline is investing heavily in a Montana manufacturing facility that specializes in the manufacture of the company’s two-year-old shingles vaccine Shingrix, which is eying blockbuster status.
At least $14 billion is needed to accelerate the fight against AIDS, tuberculosis and malaria and quell stubborn epidemics that still kill millions, the head of a global health fund said.
Two antimalarial strategies have been published from Imperial College London: new compounds that prevent the malaria parasite from infecting mosquitoes and gene-edited mosquitoes that cannot reproduce, leading to population destruction.
Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.
The U.S. FDA approved 60 Degrees Pharmaceuticals’ Arakoda (tafenoquine) tablets for the prevention of malaria in patients aged 18 years and older.